Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Hypothetical Pathogenetic Model of Membranous Nephropathy.International journal of molecular sciences · 2025
   Article
2. Mannose-Binding Lectin Deposition in Membranous Nephropathy and Differentiation of Primary from Secondary Forms.International journal of molecular sciences · 2024
   Article
3. Diagnostic Usefulness of Antibodies Against M-type Phospholipase A2 Receptor (aPLA2R) in Primary Membranous Nephropathy in the Mexican Population.Cureus · 2023
   Article
4. The Role of Anti-PLAInternational journal of environmental research and public health · 2022
   Review
5. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy.Frontiers in immunology · 2021
   Review
6. Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody Titer.Frontiers in pharmacology · 2021
   Article
7. A comparison of clinical features between idiopathic membranous nephropathy patients with and without serum antibody against phospholipase A2 receptor.Medicine · 2019
   Article
8. A Proposal for a Serology-Based Approach to Membranous Nephropathy.Journal of the American Society of Nephrology : JASN · 2017
   Review
9. Changing the concepts of immune-mediated glomerular diseases through proteomics.Proteomics. Clinical applications · 2015
   Review
10. American Society of Nephrology quiz and questionnaire 2014: glomerular diseases.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Article
11. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy.BioMed research international · 2015
    Review

Corrections and comments

• Comment on
  Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as